A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
Robert Holloway -
Sponsor
GOG Foundation
The main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with defactinib; (b) Understand the safety of VS-6766 taken alone or taken together with defactinib; (c) Describe how well and how long the study treatment with VS-6766 alone or in combination with defactinib works; and (d) Measure the amount of VS-6766, defactinib and compounds related to the two study drugs in your blood at different times (this is called pharmacokinetics).
Enrollment Form
This study is currently enrolling.